Did somebody cross the line, page-15

First 15 Last

Share
Profile

Follow
ecrawf

311 Posts.

05/09/14

14:26

Post #: 13931262
Share

Originally posted by silverfox3731 ↑

Here below Wpauls great post that got moderated..

I kept it and the one by Quacker as they are a great resource when it comes to undestanding the interim phase 2 trial results in coming months. My comment is that gennocea have set the benchmark with just over a 50% reduction in the frequency of Flairs. Hopefully AHZ can get a 100% reduction but 70 to 80% will be outstanding.

Great to be able to see the views of Julian Chick in Quackers post and welcome WPaul. Your scientific input will be most valuable.

Wpaul post hsv 5 sep.......... "My first time posting and actually the first shares that I ever purchased, so be gentle. I feel like I can shed a little light on the science aspect of vaccines, I’m a published scientific author in HIV vaccines. A therapeutic vaccine doesn't necessarily have to be curative to be therapeutic it can just mediate the virus not necessarily kill it. This is an important distinction particularly when refereeing to herpes viruses as herpes viruses infects nerve cells. The goal of the vaccine was to induce both antibody and T cell responses and the interim results already released stated that only T cells were being generated and hence the definition of therapeutic vaccine. Antibodies can provide protection prior to the virus infecting any cells and is the most important part of a prophylactic vaccine. T cells work by killing the virus infected cell, with herpes infecting nerve cells, you don’t necessarily want to kill the cell or you will have never damage and potentially very server outcomes. Interesting studies in Herpes simplex 1 (not what AHZ have been working on) showed that T cell response didn’t kill the virus but prevented the virus from killing the nerve cells. I believe this is what the therapeutic HSV-2 vaccine is based on is meditating the symptoms and consequently inhibiting the spread of the virus. A therapeutic vaccine may present even better investment opportunities as well as there is the very real potential that it will need to be given multiple times. I personally like the regenerative technology they have and continue to develop which has a lot of potential for future uses. "

Fox

Expand

Well done fox that post deserved to stay. Thanks to Wpaul for posting.

AHZ Price at posting: 15.2¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

What's causing the cost-of-living crisis, and how to navigate it